Please login to the form below

Not currently logged in
Email:
Password:

irritable bowel syndrome

This page shows the latest irritable bowel syndrome news and features for those working in and with pharma, biotech and healthcare.

Latest news

  • NHS could save £7bn with greater diagnostics use NHS could save £7bn with greater diagnostics use

    The report specifically evaluated the savings of three existing IVD tests - covering suspected heart attacks, pre-eclampsia in pregnancy and diagnosing irritable bowel syndrome (IBS) - if widely used. ... Lastly, IVDs for common bowel condition IBS could

  • Mallinckrodt pays $1.2bn for Sucampo Pharma Mallinckrodt pays $1.2bn for Sucampo Pharma

    Amitizia is the prize asset in the deal, with FDA approvals in hand for three indications - chronic idiopathic constipation as well as constipation linked to irritable bowel syndrome and chronic opioid

  • NICE backs Allergan's IBS therapy Truberzi NICE backs Allergan's IBS therapy Truberzi

    NICE has recommended routine NHS funding for Allergan's Truberzi, which is the first drug for irritable bowel syndrome with diarrhoea (IBS-D) to pass through its review process.

  • FDA approves Synergy's constipation drug Trulance FDA approves Synergy's constipation drug Trulance

    In trials, a once-daily dose of Trulance was more effective than placebo to improve the frequency of bowel movements in patients diagnosed with CIC for at least six months. ... constipation linked to irritable bowel syndrome (IBS).

  • Valeant's proposed sale of Salix to Takeda 'in jeopardy' Valeant's proposed sale of Salix to Takeda 'in jeopardy'

    Now, the Canadian company has decided to build up Salix' salesforce to push its flagship brand – Xifaxan (rifaximin) for diarrhoea caused by irritable bowel syndrome – which has been tipped by some

More from news
Approximately 0 fully matching, plus 47 partially matching documents found.

Latest Intelligence

  • Erectile dysfunction, constipation, vaginal dryness and other laughing matters Erectile dysfunction, constipation, vaginal dryness and other laughing matters

    An Irritable Bowel Syndrome campaign tackled the challenge of IBS not being taken seriously by actually using humour. ... This campaign showed doctors suffering from Irritable Disbelief Syndrome (IDS) - a brave move but exactly the perception shift

  • Taking a lean and careful approach Taking a lean and careful approach

    His pioneering research culminated in the drug, Trulance, which has received FDA approval and is being used to treat irritable bowel syndrome and chronic constipation. ... ulcerative colitis, type 1 diabetes and inflammatory bowel disease.

  • Can biosimilars live up to the hype? Can biosimilars live up to the hype?

    She is convinced that biosimilars are essential in treating patients with chronic conditions such as rheumatoid arthritis, irritable bowel syndrome and psoriasis, because they provide the same uplift in quality of

  • Oral biologics delivery still elusive Oral biologics delivery still elusive

    years. Among a newer generation of orally-delivered peptides is Ironwood Pharma's peptide drug Linzess/Constella (linaclotide) - which debuted in 2012 for constipation associated with irritable bowel syndrome. ... Among these are Avaxia Biologics, which

  • Pharma deals during April 2014 Pharma deals during April 2014

    proteinuria associated with nephrotic syndrome, certain rheumatology-related conditions, and infantile spasms. Whilst this is a 60-year old drug acquired by Questcor in 2001 for $100, 000, generic competition is ... delta opioid receptor antagonist for

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Irritable Bowel Syndrome (IBS) Patient Insights

    Irritable Bowel Syndrome: Patient–Provider Interaction and Patient Education. J Clin Med. 2018; 7(1):3. -----. ... Irritable bowel syndrome in adults: diagnosis and management. NICE Clinical Guideline 61; 2017.

  • IGNIFI

    Irritable Bowel Syndrome (IBS) Patient Insights.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics